Generate Biomedicines, Inc.
generatebiomedicines.comGenerate Biomedicines Inc (GENB) is a clinical-stage biopharmaceutical company that uses an AI-powered platform, called the Generate Platform, to discover and develop protein-based therapeutic candidates. Revenue is derived from collaboration agreements, recorded as collaboration revenue on the income statement, with no product sales reported as of Q1 2026. The company operates at a net loss, funding operations through equity financing, including an initial public offering completed in early 2026 during which convertible preferred stock converted into common stock. The Generate Platform incorporates AI to identify therapeutic candidates, predict biological outcomes, and support drug development programs. As a pre-commercial biotechnology company, Generate Biomedicines depends on partnership and licensing arrangements for near-term revenue, and is subject to the typical drug development pipeline risks including regulatory approval uncertainty and reimbursement dependence on government and private payors. The company filed its 10-Q on May 7, 2026, covering the three months ended March 31, 2026.
Products & Services
The Generate Platform: an AI-integrated drug discovery and development platform used to identify viable therapeutic candidates, predict biological outcomes, and produce reproducible results. The company develops protein-based therapeutic product candidates advanced through this platform.
Revenue Model
Collaboration revenue from partnership and licensing arrangements. No product revenue reported as of Q1 2026 (three months ended March 31, 2026). Deferred revenue, both current and non-current, appears on the balance sheet, indicating upfront payments from collaboration partners recognized over time.
Customers & Markets
Collaboration partners in the pharmaceutical and biotechnology industry. End markets include human therapeutics subject to regulatory approval and third-party payor reimbursement, including Medicare, Medicaid, and managed care organizations.
Geographic Exposure
The filing references foreign currency exchange impacts and mentions geopolitical risks, but does not specify revenue by geography. Primary regulatory focus appears to be U.S.-based given references to Medicare, Medicaid, and U.S. Regulatory Authorities.
Source: SEC 10-Q, filed 2026-05-07
Financial Snapshot
Loading...
